Termination of a Material Definitive Agreement. The information set forth in

Entry into a Material Definitive Agreement. On August 31, 2026 through September 3, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a total of five exchange agreements (the “Exchange Agreements”) and, for each, a corresponding partitioned promissory note (together, the “Partitioned Promissory Notes”) with Streeterville Capital, LLC (the “Lender”) related to that certain Promissory Note dated February 16, 2024 (the “Promissory Note”). Pursuant to the Exchange Agreements and Partitioned…

Unregistered Sales of Equity Securities. The information set forth in

Regulation FD Disclosure. On August 11, 2026, the online media company Breaking Defense ( https://breakingdefense.com ) published an article authored by Thomas K. Equels, the Chief Executive Officer of AIM ImmunoTech Inc. (the “Company”). The article, titled “Biodefense is force protection: Ready today, prepared for tomorrow,” discusses the importance of military force readiness, specifically how the Company’s drug Ampligen (rintatolimod) has potential as a broad-spectrum early-onset and/or p…

Results of Operations and Financial Condition. On August 10, 2026, AIM ImmunoTech Inc. (the “Company”) issued a press release (the “Press Release”) announcing its financial results for the quarter ended June 30, 2026. A copy of the Press Release is attached to this Current Report on Form 8-K as Exhibit 99.1 and, other than the quotes by Thomas Equels, is incorporated herein by reference. The information in this report, including Exhibit 99.1 attached hereto, is being furnished and shall not b…

Entry into a Material Definitive Agreement. On July 31, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a proposal (the “Proposal Agreement”) with Sterling Pharma Solutions (the “Manufacturer”) that is related to the Master Service Agreement and a Quality Agreement entered into between the Company and the Manufacturer in 2022. Pursuant to the Proposal Agreement, the Manufacturer agreed to manufacture further batches of the polynucleotide drug substances PolyI and Poly C12U and transfer…

Termination of a Material Definitive Agreement As previously disclosed, AIM ImmunoTech Inc. (the “Company”) is a party to the Equity Distribution Agreement (the “Agreement”), dated April 1, 2025, as amended on April 10, 2026, with Maxim Group LLC (the “Sales Agent”), pursuant to which the Company was able to sell shares of common stock in sales deemed to be an “at the market offering” as defined in Rule 415 promulgated under the Securities Act of 1933, as amended. On July 31, 2026, the Compan…

Entry into a Material Definitive Agreement. Securities Purchase Agreement On June 9, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 2,554,119 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.5189…

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. Securities Purchase Agreement On May 20, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors (the “Investors”), pursuant to which the Company agreed to issue and sell to such investors in a registered direct offering 7,519,351 shares (the “Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company, at an offering price of $0.325…

Unregistered Sales of Equity Securities. The information set forth in

Entry into a Material Definitive Agreement. As previously disclosed, AIM ImmunoTech Inc. (the “Company”) previously issued to Streeterville Capital, LLC (the “Lender”) a Promissory Note in the original principal amount of $3,301,250.00 dated February 16, 2024 (the “Note”) pursuant to a Note Purchase Agreement between the Company and the Lender. The Company and the Lender subsequently extended the maturity date of the Note to June 30, 2026. On May 18, 2026, the Company and the Lender entered i…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in

to the extent required. The information, including Exhibit 99.1, referenced in this Item 2.02, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), if and to the extent such subsequent filing specif…

Unregistered Sales of Equity Securities. As previously reported, AIM ImmunoTech Inc. (the “Company”) entered into that certain warrant exercise inducement offer letter agreement, dated May 7, 2026 (the “Inducement Letter”) with holders (the “Holders”) of (i) Class A and Class B warrants to purchase common stock, par value $0.001 per share (the “Common Stock”), of the Company, issued on May 31, 2024; (ii) Class C and Class D Common Stock purchase warrants issued on September 30, 2024; and (iii…

Unregistered Sales of Equity Securities. The Company issued the Inducement Warrants pursuant to the exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), available under Section 4(a)(2). Neither the Inducement Warrants nor the Inducement Warrant Shares have been registered under the Securities Act, and such securities may not be offered or sold in the United States absent registration or an exemption from registration under the Securiti…

Entry into a Material Definitive Agreement. On May 7, 2026, AIM ImmunoTech Inc. (the “Company”) entered into a warrant exercise inducement offer letter agreement (the “Inducement Letter”) with holders (the “Holders”) of (i) Class A and Class B common stock purchase warrants issued on May 31, 2024 (the “Existing May 2024 Warrants”), exercisable for up to an aggregate of 112,819 shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), (ii) Class C and Class D Commo…

Entry into a Material Definitive Agreement. On April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market pub…

Entry into a Material Definitive Agreement. Warrant Agency Agreement On March 6, 2026, in connection with the closing of its previously announced Rights Offering (defined below), AIM ImmunoTech Inc. (the “ Company ”) entered into a Warrant Agency Agreement with Equiniti Trust Company, LLC (“ EQ ”), pursuant to which EQ agreed to act as warrant agent with respect to warrants included in the units issued by the Company in the Rights Offering. A copy of the Warrant Agency Agreement is filed as E…

Other Events. On March 6, 2026, the Company completed its previously announced rights offering (the “ Rights Offering ”) pursuant to its effective registration statement on Form S-1, as amended (Registration No. 333-292085), previously filed with and declared effective by the Securities and Exchange Commission (the “ SEC ”), a prospectus and a prospectus supplement filed with the SEC. Pursuant to the Rights Offering, the Company sold an aggregate of 1,842 units consisting of an aggregate of 1…

Material Modification to Rights of Security Holders. The disclosure contained in

Other Events. A Phase I/II Open Label Study of Durvalumab (Imfinzi) and Rintatolimod (Ampligen) in pancreatic cancer patients with stable disease Post-FOLFIRINOX is being conducted. Attached hereto as Exhibit 99.2 is an interim clinical progress update for this study which is incorporated by reference herein. Please see Exhibit 99.2 for more detailed information. Cautionary Statement Regarding Forward-Looking Statements Some of the statements included in the documents filed herewith may be fo…

Regulation FD Disclosure. Furnished herewith as Exhibits 99.1 and 99.2, respectively, are a January 20, 2026 Notice of Change and Modifications of Class E Common Stock Purchase Warrants and a January 20, 2026 Notice of Change and Modifications of Class F Common Stock Purchase Warrants that were sent to the holders of these warrants. The information, including Exhibits 99.1 and 99.2 referenced herein, are “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities…

Regulation FD Disclosure. Furnished herewith as Exhibit 99.1 is AIM’s January 2026 Corporate Presentation. The information, including Exhibit 99.1 referenced herein, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Information set forth in